ISRG INTUITIVE SURGICAL INC
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1035267 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.5%
TTM net income YoY7.7%
TTM EPS YoY9.4%
Revenue 3-yr CAGR19.1%
Net income 3-yr CAGR24.9%
Margins
Gross margin67.2%
Operating margin28.4%
Net margin25.5%
FCF margin31.1%
EBITDA margin—
Returns
ROE18.0%
ROA15.3%
ROIC (approx.)19.9%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio3.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.38x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $10.06B | $8.35B | $7.12B | $6.22B | $5.71B |
| Cost of revenue | $3.42B | $2.72B | $2.39B | $2.03B | $1.75B |
| Gross profit | $6.64B | $5.63B | $4.73B | $4.20B | $3.96B |
| R&D expense | $1.31B | $1.15B | $998.80M | $879.00M | $671.00M |
| SG&A expense | $2.38B | $2.14B | $1.96B | $1.74B | $1.47B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B |
| Pretax income | $3.31B | $2.67B | $1.96B | $1.61B | $1.89B |
| Income tax | $434.80M | $336.30M | $141.60M | $262.40M | $162.20M |
| Net income | $2.86B | $2.32B | $1.80B | $1.32B | $1.70B |
| EBITDA | $3.55B | $2.79B | $2.15B | $1.90B | $2.10B |
| EPS (basic) | 8.00 | 6.54 | 5.12 | 3.72 | 4.79 |
| EPS (diluted) | 7.87 | 6.42 | 5.03 | 3.65 | 4.66 |
| Weighted avg. shares (diluted) | 362.70M | 362.00M | 357.40M | 362.00M | 365.80M |
| Balance sheet | |||||
| Cash & equivalents | $3.37B | $2.06B | $2.77B | $1.60B | $1.31B |
| Short-term investments | $2.57B | $1.99B | $2.47B | $2.54B | $2.91B |
| Receivables | $1.53B | $1.23B | $1.13B | $942.10M | $782.70M |
| Inventory | $1.84B | $1.49B | $1.22B | $893.20M | $587.10M |
| Current assets | $9.78B | $7.11B | $7.89B | $6.25B | $5.84B |
| PP&E, net | $5.34B | $4.65B | $3.54B | $2.37B | $1.88B |
| Goodwill | $370.30M | $347.50M | $348.70M | $348.50M | $343.60M |
| Intangibles | $17.10M | $23.00M | $39.10M | $49.80M | $70.50M |
| Total assets | $20.46B | $18.74B | $15.44B | $12.97B | $13.55B |
| Current liabilities | $2.01B | $1.75B | $1.66B | $1.42B | $1.15B |
| Total liabilities | $2.52B | $2.21B | $2.04B | $1.86B | $1.60B |
| Shareholders' equity | $17.82B | $16.43B | $13.31B | $11.04B | $11.90B |
| Shares outstanding | 355.10M | 356.60M | 352.30M | 350.00M | 357.70M |
| Cash flow statement | |||||
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Capital expenditure | $539.80M | $1.11B | $1.06B | $532.40M | $339.50M |
| Free cash flow | $2.49B | $1.30B | $749.60M | $958.40M | $1.75B |
| Investing cash flow | $665.80M | -$3.27B | -$360.10M | $1.37B | -$2.46B |
| Financing cash flow | -$2.36B | $150.90M | -$287.60M | -$2.57B | $43.00M |
| Depreciation & amortization | $600.00M | $439.00M | $382.00M | $326.00M | $280.00M |
| Stock-based compensation | $788.20M | $676.80M | $592.80M | $513.20M | $449.20M |
| Share buybacks | $2.30B | $0 | $416.30M | $2.61B | $0 |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.